HXOH yields 6.69% · JNJ yields 2.13%● Live data
📍 HXOH pulled ahead of the other in Year 1
Combined, HXOH + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HXOH + JNJ for your $10,000?
Hexion Holdings Corporation, through its subsidiaries, produces and sells adhesives and performance materials in the United States, Canada, Europe, Asia, Latin America, Australia, and New Zealand. The company offers wood adhesives products, such as phenol formaldehyde, amino resins comprising urea formaldehyde and melamine formaldehyde, laminates, and derivatives for plywood, particleboard, oriented strand board, medium density fiberboard, laminated veneer lumber particleboard, laminated beams, cross-laminated timber, truck-decking, and glass mat applications. It also provides wax emulsions for panel board and specialty applications; intermediates and derivatives, such as urea formaldehyde concentrate, methaform, and triazines for methylene diphenyl diisocyanate, butanediol, herbicides and fungicides, oil and gas production scavengers, fabric softeners, formaldehyde-based resins, and hydrogen sulfide scavenging for oil and gas applications. In addition, the company offers performance coatings products, including Versatic acid derivatives for automotive, industrial, protective, architectural, construction, and adhesives applications; and chemical intermediates, such as Versatic acids and neo-acids for catalysts (peroxides), pharmaceuticals, agrochemicals, and adhesion promoters. It serves residential and non-residential construction, energy, automotive, and agriculture industries. The company was incorporated in 2019 and is headquartered in Columbus, Ohio.
Full HXOH Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.